Browse All Available Clinical Trials
Join Now to be Notified of New Clinical Trials
View Information and Clinical Trials for Other Conditions
Attention-Deficit Hyperactivity Disorder
Attention-deficit hyperactivity disorder (ADHD) previously known as Attention Deficit Disorder (ADD), is generally considered to be a
developmental disorder, largely neurological in nature, affecting about 5% of the world's population. The disorder typically presents
itself during childhood, and is characterized by a persistent pattern of inattention and/or hyperactivity, as well as forgetfulness, poor impulse
control or impulsivity, and distractibility. ADHD is currently considered to be a persistent and chronic condition for which no medical cure
is available. ADHD is most commonly diagnosed in children and, over the past decade, has been increasingly diagnosed in adults. About 60% of children
diagnosed with ADHD retain the disorder as adults. Studies show that there is a familial transmission of the disorder which does not occur through
adoptive relationships. Twin studies indicate that the disorder is highly heritable and that genetics contribute about three quarters of the total
ADHD population. While the majority of ADHD is believed to be genetic in nature, roughly 1/5 of all ADHD cases are thought to be acquired after
conception due to brain injury caused by either toxins or physical trauma prenatally or postnatally. According to a majority of medical research in
the United States, as well as other countries, ADHD is today generally regarded as a chronic disorder for which there are some effective treatments.
Over 200 controlled studies have shown that stimulant medication is an effective way to treat ADHD. Methods of treatment usually involve some
combination of medication, behaviour modification, life style changes, and counseling. Certain social critics are highly skeptical that the diagnosis
denotes a genuine impairment and question virtually all that is known about ADHD. The symptoms of ADHD are not as profoundly different from normal
behavior as are those of other chronic mental disorders. Still, ADHD has been shown to often impair functioning, and many adverse life outcomes are
associated with ADHD.
Current Research
For current research articles click
- here
Classification
ADHD is a developmental disorder that is often said to be neurological in nature. The term "developmental" means that certain traits such as impulse
control significantly lag in development when compared to the general population. This developmental lag has been estimated to range between 30-40
percent in ADHD sufferers in comparison to their peers; consequently these delayed attributes are considered an impairment. ADHD has also been
classified as a behavior disorder and a neurological disorder or combinations of these classifications such as neurobehavioural or neurodevelopmental
disorders. These compounded terms are now more frequently used in the field to describe the disorder. The behavioral classification for ADHD is not
completely accurate in that those with Predominately Inattentive ADHD often display few or no overt behaviors.
Diagnosis
Based on DSM-IV criteria, three types of ADHD are identified:
- ADHD, Combined Type: if both criteria 1A and 1B are met for the past 6 months
- ADHD Predominantly Inattentive Type: if criterion 1A is met but criterion 1B is not met for the past six months
- ADHD, Predominantly Hyperactive-Impulsive Type: if Criterion 1B is met but Criterion 1A is not met for the past six months.
ICD
In the tenth edition of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) the symptoms of ADHD are given
the name "Hyperkinetic disorders". When a conduct disorder (as defined by ICD-10) is present, the condition is referred to as "Hyperkinetic
conduct disorder". Otherwise the disorder is classified as "Disturbance of Activity and Attention", "Other Hyperkinetic Disorders" or "Hyperkinetic
Disorders, Unspecified". The latter is sometimes referred to as, "Hyperkinetic Syndrome".
The American Academy of Pediatrics Clinical Practice Guideline for children with ADHD emphasizes that a reliable diagnosis is dependent upon the
fulfillment of three criteria:
- The use of explicit criteria for the diagnosis using the DSM-IV-TR.
- The importance of obtaining information about the child’s symptoms in more than one setting.
- The search for coexisting conditions that may make the diagnosis more difficult or complicate treatment planning.
The first criterion can be satisfied by using an ADHD-specific instrument such as the Conners' Rating Scale. The second criterion is best fulfilled
by examining the individual's history. This history can be obtained from parents and teachers, or a patient's memory. The requirement that symptoms
be present in more than one setting is very important because the problem may not be with the child, but instead with teachers or parents who are too
demanding. The use of intelligence testing, psychological testing, and neuropsychological testing (to satisfy the third criterion) is essential in
order to find or rule out other factors that might be causing or complicating the problems experienced by the patient.
The Centers for Disease Control and Prevention (CDC) state that a diagnosis of ADHD should only be made by trained health care providers, as many of
the symptoms may also be part of other conditions, such as bodily illness or other physiological disorders, such as hyperthyroidism. It is not uncommon
that physically and mentally nonpathological individuals exhibit at least some of the symptoms from time to time. Severity and pervasiveness of the
symptoms leading to prominent functional impairment across different settings (school, work, social relationships) are major factors in a positive
diagnosis.
Adults often continue to be impaired by ADHD. Adults with ADHD are diagnosed under the same criteria, including the stipulation that their symptoms
must have been present prior to the age of seven. Adults face some of their greatest challenges in the areas of self-control and self-motivation,
as well as executive functioning, usually having more symptoms of inattention and fewer of hyperactivity or impulsiveness than children do.
Common comorbid conditions are Oppositional Defiance Disorder (ODD). About 20% to 25% of children with ADHD meet criteria for a learning disorder.
Learning disorders are more common when there are inattention symptoms.
Causes
The exact cause of ADHD remains unknown and in all probability ADHD is a heterogeneous disorder, meaning that several causes could create very
similar symptomology. Still, there is a wide body of evidence which indicates that the overriding cause of ADHD is genetics. Research suggests
that a large majority of ADHD arises from a combination of various genes, many of which affect dopamine transporters. Suspect genes include the
10-repeat allele of the DAT1 gene, the 7-repeat allele of the DRD4 gene, and the dopamine beta hydroxylase gene (DBH TaqI). Additionally, SPECT
scans found people with ADHD to have reduced blood circulation, and a significantly higher concentration of dopamine transporters in the striatum
which is in charge of planning ahead.
A study by the U.S. Department of Energy’s Brookhaven National Laboratory in collaboration with Mount Sinai School of Medicine in New York suggest
that it is not the dopamine transporter levels that indicate ADHD, but the brain's ability to produce dopamine itself. The study was done by injecting
20 ADHD subjects and 25 control subjects with a radiotracer that attaches itself to dopamine transporters. The study found that it was not the
transporter levels that indicated ADHD, but the dopamine itself. ADHD subjects showed lower levels of dopamine across the board. They speculated that
since ADHD subjects had lower levels of dopamine to begin with, the number of transporters in the brain was not the telling factor. In support of
this notion, plasma homovanillic acid, an index of dopamine levels, was found to be inversely related not only to childhood ADHD symptoms in adult
psychiatric patients, but to "childhood learning problems" in healthy subjects as well.
An early PET scan study found that global cerebral glucose metabolism was 8.1% lower in medication-naive adults who had been diagnosed as ADHD while
children. The image on the right illustrates glucose metabolism in the brain of a 'normal' adult while doing an assigned auditory attention task; the
image on the right illustrates the areas of activity in the brain of an adult who had been diagnosed with ADHD as a child when given that same task;
these are not pictures of individual brains, which would contain substantial overlap, these are images constructed to illustrate group-level differences.
Additionally, the regions with the greatest deficit of activity in the ADHD patients (relative to the controls) included the premotor cortex and the
superior prefrontal cortex. A second study in adolescents failed to find statistically significant differences in global glucose metabolism between
ADHD patients and controls, but did find statistically significant deficits in 6 specific regions of the brains of the ADHD patients (relative to
the controls). Most notably, lower metabolic activity in one specific region of the left anterior frontal lobe was significantly inversely correlated
with symptom severity. These findings strongly imply that lowered activity in specific regions of the brain, rather than a broad global deficit,
is involved in ADHD symptoms. However, these readings are of subjects doing an assigned task. They could be found in ADHD diagnosed patients because
they simply were not attending to the task. Hence the parts of the brain used by others doing the task would not show equal activity in the ADHD
patients.
The estimated contribution of non genetic factors to the contribution of all cases of ADHD is 20 percent. The environmental factors implicated are
common exposures and include alcohol, in utero tobacco smoke and lead exposure. Lead concentration below the Center for Disease Control's action level
account for slightly more cases of ADHD than tobacco smoke (290 000 versus 270 000, in the USA, ages 4 to 15). Complications during pregnancy and
birth—including premature birth—might also play a role. It has been observed that women who smoke while pregnant are more likely to have children with
ADHD. This could be related to the fact that nicotine is known to cause hypoxia (lack of oxygen) in utero, but it could also be that ADHD women have
more probabilities to smoke both in general and during pregnancy, being more likely to have children with ADHD due to genetic factors.
Head injuries can cause a person to present ADHD-like symptoms, possibly because of damage done to the patient's frontal lobes. Because these types of
symptoms can be attributable to brain damage, the earliest designation for ADHD was "Minimal Brain Damage".
There is no compelling evidence that social factors alone can create ADHD. Many researchers believe that attachments and relationships with caregivers
and other features of a child's environment have profound effects on attentional and self-regulatory capacities. It is noteworthy that a study of foster
children found that an inordinate number of them had symptoms closely resembling ADHD. An editorial in a special edition of Clinical Psychology in
2004 stated that "our impression from spending time with young people, their families and indeed colleagues from other disciplines is that a medical
diagnosis and medication is not enough. In our clinical experience, without exception, we are finding that the same conduct typically labelled ADHD
is shown by children in the context of violence and abuse, impaired parental attachments and other experiences of emotional trauma." Furthermore,
Complex Post Traumatic Stress Disorder can result in attention problems that can look like ADHD, as can Sensory Integration Disorders.
Despite the lack of evidence that nutrition causes ADHD, studies have found that malnutrition is correlated with attention deficits.
Treatment
There are several clinically proven effective options available to treat people diagnosed with ADHD. ADHD is treated most effectively, and cost
efficiently, with medication. Psychotherapy is another option, with or without medication Omega-3 fatty acids, zinc, and magnesium may have
benefits with regards to ADHD symptoms.
Comorbid disorders or substance abuse can make finding the proper diagnosis and the right overall treatment more costly and time-consuming.
Prognosis
ADHD is a developmental disorder meaning that certain traits will be delayed in the ADHD individual. These traits will develop but just at a much
slower rate than the average person. With ADHD it has been estimated that this lag could be as high as thirty to forty percent in the development of
impulse control. Symptoms of ADHD are often seen by the time a child enters preschool. Those with ADHD typically have a greater degree of parent-child
conflict and emotional reactivity. The incidence of speech problems, central auditory processing difficulties, and coordination problems are all
higher than that of the general population. A marked decrease in academic skills such as reading, spelling, or math is common with children who
have ADHD.
During the elementary years an ADHD student will have more difficulties with work completion, productivity, planning, remembering things needed for
school, and meeting deadlines. Oppositional and socially aggressive behaviour is seen in 40-70 percent of children at this age. Even ADHD kids with
average to above average intelligence show "chronic and severe underachievement". Fully 46% of those with ADHD have been suspended and 11% expelled.
Thirty seven percent of those with ADHD do not get a high school diploma even though many of them will receive special education services. The combined
outcomes of the expulsion and dropout rates indicate that almost half of all ADHD students never finish highschool. Only five percent of those
with ADHD will get a college degree compared to twenty seven percent of the general population. (US Census, 2003)
Social impairment for those with ADHD are seen at both school and work. They often have more troubled relationships with peers or family members. At
the workplace they change jobs more often and are more likely to get fired. Their income level does not rise as quickly as their peers even when
education level, IQ, and their neighborhood is accounted for. Thirty five percent of all those with ADHD will be self employed in their mid-thirties.
Those with ADHD are at greater risk of: injury, abnormal risk taking, smoking, having learning disabilities, other mental disorders, teen pregnancy,
substance abuse, involvement with the criminal justice system, and having a poorer driving record.
Prevention
There is no known way to prevent ADHD. Some studies indicate an association between mothers who smoke during pregnancy and a higher rate of ADHD in
their children. Avoiding smoking, alcohol, and drugs during pregnancy may help prevent a higher risk of developing ADHD or similar behaviour in
offspring.
Epidemiology
ADHD's prevalence worldwide is estimated to be a bit over 5%, with most of the reported variability being due to methodological characteristics of
studies. 10% of males, and (only) 4% of females have been diagnosed in the U.S. This apparent sex difference may reflect either a difference in
susceptibility or that females with ADHD are less likely to be diagnosed than males.
History
Some sources claim to have identified historical and literary references to ADHD before 1900, however, the condition we refer to as "ADHD" dates to the
mid-twentieth century, when physicians developed a diagnosis for a set of conditions variously referred to as "minimal brain damage", "learning/behavioural
disabilities" or "hyperactivity".
In 493 BC, physician-scientist Hippocrates described a condition that seems to be compatible with what we now know as ADHD. He described patients who
had "quickened responses to sensory experience, but also less tenaciousness because the soul moves on quickly to the next impression". Hippocrates
attributed this condition to an "overbalance of fire over water”. His remedy for this "overbalance" was "barley rather than wheat bread, fish rather
than meat, water drinks, and many natural and diverse physical activities." Shakespeare made reference to a "malady of attention", in King Henry VIII.
In 1845, Dr. Heinrich Hoffmann (a German physician and poet who wrote books on medicine and psychiatry) became interested in writing for children
when he couldn't find suitable materials to read to his 3-year-old son. The result was a book of poems, complete with illustrations, about children
and their undesirable behaviours. "Die Geschichte vom Zappel-Philipp" (The Story of Fidgety Philip) in Der Struwwelpeter was a description of a little
boy who could be interpreted as having attention deficit hyperactivity disorder, or as merely a moral fable to amuse young children and encourage them
to behave properly.
In 1902 the English pediatrician George Still gave a series of lectures to the Royal College of Physicians in England, and described a condition which
some have claimed is analogous to ADHD. Still described a group of children with significant behavioral problems, caused, he believed, by an innate
hereditary dysfunction and not by poor child rearing or environment. However, analysis of Still's descriptions by Palmer and Finger indicated that
the qualities Still described are not "considered primary symptoms of ADHD".
The 1918–1919
influenza pandemic left many survivors with encephalitis, affecting their neurological functions. Some of these exhibited immediate
behavioral problems which may correspond to ADHD (although no diagnosis for such a disorder existed at the time). This caused many later commentators
to believe that the condition was the result of injury rather than heredity. The concept of hyperactivity not being caused by brain damage was first
described by Stella Chess as, ""Hyperactive Child Syndrome" in 1960. This caused a significant rift in the understanding of the disorder. Europeans
saw hyperkinesis as unusual and often associated it with retardation, brain damage, and conduct disorders, and changes to the ICD were not made until
1994. In the USA by 1966, following observations that the condition existed without any objectively observed pathological disorder or injury,
researchers changed the terminology from Minimal Brain Damage to Minimal Brain Dysfunction.
In 1937 a Dr. Bradley in Providence, RI reported that a group of children with behavioral problems improved after being treated with stimulant
medication. In 1957 the stimulant methylphenidate (Ritalin) became available. In its various forms (Ritalin, Focalin, Concerta, Metadate, and
Methylin), it remains one of the most widely prescribed medications for ADHD. Ritalin was first produced in 1950. Initially the drug was used to
treat
narcolepsy, chronic fatigue,
depression, and to counter the sedating effects of other medications. The drug began to be used for ADHD in the
1960s and steadily rose in use. In 1975 Pemoline (Cylert) was approved by the FDA for use in the treatment of ADHD. While an effective agent for
managing the symptoms, the development of liver failure in 14 cases over the next 27 years would result in the manufacturer withdrawing this medication
from the market. New delivery systems for medications were invented in 1999 that eliminated the need for multiple doses across the day or taking
medication at school. These new systems include pellets of medication coated with various time-release substances to permit medications to
dissolve hourly across an 8–12 hour period (Medadate CD, Adderall XR, Focalin XR) and an osmotic pump that extrudes a liquid methylphenidate sludge
across an 8–12 hour period after ingestion (Concerta). In 2003 – Atomoxetine (Strattera) received the first FDA approval for a nonstimulant drug
to be used specifically for ADHD. In 2007 Lisdexamfetamine becomes the first prodrug to receive FDA approval for ADHD. The landmark study of 1999 –
The largest study of treatment for ADHD in history – is published in the American Journal of Psychiatry. Known as the Multimodal Treatment Study of
ADHD (MTA Study), it involved more than 570 children with ADHD at 6 sites in the United States and Canada randomly assigned to 4 treatment groups.
Results generally showed that medication alone was more effective than psychosocial treatments alone, but that their combination was beneficial for
some subsets of ADHD children beyond the improvement achieved only by medication. More than 40 studies have subsequently been published from this
massive dataset.
Psychiatry first codified a condition called “hyperkinetic reaction of childhood” in 1968, displaying the psychoanalytical influences of that time.
The name Attention Deficit Disorder (ADD) was first introduced in DSM-III, the 1980 edition. By 1987 – The DSM-IIIR was released changing the diagnosis
to "Undifferentiated Attention Deficit Disorder." Further revisions to the DSM were made in 1994 – DSM-IV described three groupings within ADHD, which
can be simplified as: mainly inattentive; mainly hyperactive-impulsive; and both in combination. During 1996, ADHD accounted for at least 40% of
child psychiatry references.
Controversy
The ADHD diagnosis has been questioned on many fronts. Some critics focus upon the positive traits that people with ADHD are thought to have,
such as "hyperfocusing." Others believe ADHD is a divergent or normal-variant human behavior (using the term neurodiversity to describe this idea),
emphasizing that human behaviour is immensely variable and "ADHD" may simply represent one part of the spectrum. Such critics sometimes allege
that ADHD is not actually a discrete condition and question why it should be treated with drugs. Others dispute the alleged genetic basis of ADHD.
(adapted from Wikipedia, the free encyclopedia http://en.wikipedia.org/wiki/Adhd)
Genetic and Environmental Contributions to Retrospectively Reported DSM-IV Childhood Attention Deficit Hyperactivity Disorder
Authors: Haberstick BC, Timberlake D, Hopfer CJ, Lessem JM, Ehringer MA, Hewitt JK.
Department of Psychiatry, University of Colorado Health Science Center, Denver, CO, USA.
BACKGROUND: A variety of methodologies and techniques converge on the notion that adults and children with attention deficit hyperactivity disorder
(ADHD) have similar deficits, but there is limited knowledge about whether adult retrospective reports reflect similar genetic and environmental
influences implicated in childhood ADHD.MethodDSM-IV ADHD symptoms were collected retrospectively from 3896 young adults participating in the National
Longitudinal Study of Adolescent Health. Responses from this genetically informative sample of same- and opposite-sex twins and siblings were used to
determine the magnitude of genetic and environmental influences. Possible gender differences in these effects were also examined. The degree of familial
specificity of the genetic and environmental influences on the Inattentive and Hyperactive-Impulsive symptom dimensions was also determined. RESULTS:
Additive genetic effects contributed moderately to DSM-IV Inattentive, Hyperactive-Impulsive and Combined ADHD subtypes (heritability estimates of
0.30-0.38). Individual-specific influences accounted for the remaining proportion of the variance. Both genetic and individual-specific environmental
effects contributed to the covariation of Inattentive and Hyperactive-Impulsive symptomologies. CONCLUSIONS: Results from our genetic analyses agree
with previous findings based on self-assessment of current and retrospectively reported ADHD symptoms in adolescents and adults. Large individual-specific
environmental influences as identified here suggest that current questionnaires used for retrospective diagnoses may not provide the most accurate
reconstruction of the etiological influences on childhood ADHD in general population samples.
Journal: Psychol Med. 2007 Sep 25;:1-10
Adapted from PubMed; click here to access full journal article.
The Consequences of Attention-Deficit/Hyperactivity Disorder in Adults
Authors: Goodman DW.
GOODMAN: Johns Hopkins at Green Spring Station, Lutherville, MD.
Until recently, attention-deficit/hyperactivity disorder (ADHD) was a diagnosis reserved for children and adolescents as it was believed to dissipate
before adulthood. New evidence, however, supports the persistence of ADHD beyond adolescence, and it is now recognized as a chronic neurobehavioral
disorder in adults. Adults with ADHD have difficulties with school, work, family interactions, and social activities. Although treatments are available
for adult ADHD, many patients never receive an accurate diagnosis that would afford them appropriate therapeutic intervention. If left untreated, adult
ADHD can cause significant personal, social, and economic burdens that can have a negative impact on overall quality of life. This article discusses how
ADHD presents in adults and the effects of the disorder on educational, occupational, interpersonal, and social functioning. Currently available
treatments for ADHD in adults are also reviewed.
Journal: J Psychiatr Pract. 2007 Sep;13(5):318-27.
Adapted from PubMed; click here to access full journal article.
Emerging Drugs for Attention-Deficit/Hyperactivity Disorder
Authors: Weisler RH.
Duke University Medical Center, Durham, NC, USA. rweisler@aol.com
Symptoms of attention-deficit/hyperactivity disorder (ADHD) are heterogeneous and often accompanied by comorbid psychiatric disorders. Although symptoms
tend to lessen with age, many patients continue to be affected by the disorder into adulthood. Although many medications are available to treat ADHD, it
is unlikely that a single medication will ever be developed to work for all patients. Recent advances, such as long-acting, extended-release formulations
and transdermal delivery systems, have lengthened the duration of effectiveness, which has increased compliance and eliminated the need for additional
medication dosing during the school or work day. Additional safe, well-tolerated, long-acting medications with further reduced potential for diversion
and abuse are needed. Catecholamine pathways and their effect on executive functions and ADHD symptom control have been productive areas of research.
Potential therapies such as adrenergic receptor agonists, glutamatergic agents, GABA receptor antagonists and nicotine receptor agonists are being
explored as future pharmacotherapies for ADHD.
Journal: Expert Opin Emerg Drugs. 2007 Sep;12(3):423-34.
Adapted from PubMed; click here to access full journal article.
Continuity in Methylphenidate Treatment of Adults with Attention-Deficit/Hyperactivity Disorder
Authors: Olfson M, Marcus SC, Zhang HF, Wan GJ.
BACKGROUND: Although stimulant therapy is commonly discontinued early in adults with attention-deficit/hyperactivity disorder (ADHD), the factors that
contribute to continuity of stimulant therapy remain largely unknown. OBJECTIVE: To (1) compare the continuity of methylphenidate (MPH) therapy among
adults who use immediate-release methylphenidate (IR-MPH) for ADHD with adults who use extended-release methylphenidate (ER-MPH) formulations, and (2)
examine some of the methodological issues involved in research with administrative claims for ADHD. METHODS: An analysis of pharmacy and medical claims
for 75 US managed care plans representing approximately 55 million beneficiaries for dates of service from January 1, 2000 through December 31, 2004.
Patients had to be adults (aged 18 to 64 years) who had 1 or more outpatient medical claims for ADHD (International Classification of Diseases, Ninth
Revision, Clinical Modification code 314.xx) during the study period and who had initiated ER-MPH or IR-MPH treatment for ADHD. The study cohorts did
not have a pharmacy claim for MPHs, amphetamines, pemoline, or atomoxetine for 6 months preceding the first (index) MPH pharmacy claim. Stimulant
treatment episodes were defined to start on the index date and terminate on the last date supplied of the index medication. Episodes of treatment were
also defined as terminated if there was a gap of e30 days between the end of the days supplied on the pharmacy claim and the date of the next pharmacy
claim for the index medication. RESULTS: Less than one third (30.0%) of the adult patients who were prescribed MPH had 1 or more medical claims with a
diagnosis code for ADHD. For the adult MPH patients with at least 1 medical claim with a diagnosis code for ADHD, the patients who initiated therapy
with ER-MPH (N = 2,833) were significantly younger, were more likely to be male, and were less likely to be treated by a psychiatrist than were the
patients who initiated therapy with IR-MPH (N = 2,289). Only 50.5% (n =1,156) of IR-MPH patients and 61.4% (n =1,739) of ER-MPH patients had more than
1 pharmacy claim for the index MPH medication. Adults treated with ER-MPH also had a significantly longer median duration of treatment with the index
medication (ER-MPH: 68 days, 95% confidence interval (CI), 65-71 days vs. IR-MPH 39 days, 95% CI, 33-52 days). Controlling for group differences in age,
gender, treatment by a psychiatrist, recently prescribed psychotropic medications, treated mental disorders, emergency mental health treatment, and
inpatient mental health care, ER-MPH initiation was associated with an average 27% longer duration of treatment than with IR-MPH (survival time ratio:
1.27, 95% CI, 1.20-1.35). CONCLUSION: In management of adult ADHD, use of ER-MPH formulations was associated with a longer median duration of the
initially prescribed medication than was use of IR-MPH. It is unknown whether the observed absolute unadjusted difference of 29 days in median length
of therapy is clinically important.
Journal: J Manag Care Pharm. 2007 Sep;13(7):570-7.
Adapted from PubMed; click here to access full journal article.
Responsiveness of the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life Scale (AAQoL)
Authors: Matza LS, Johnston JA, Faries DE, Malley KG, Brod M.
Center for Health Outcomes Research at UBC, 7101 Wisconsin Avenue, Suite 600, Bethesda, MD, 20814, USA, louis.matza@unitedbiosource.com.
AIMS: This study examined responsiveness of the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life Scale (AAQoL), which was developed to
assess health-related quality of life (HRQL) among adults with attention-deficit/hyperactivity disorder (ADHD). METHODS: Adults with ADHD completed the
AAQoL, Conners' Adult ADHD Rating Scale (CAARS), SF-36, and Endicott Work Productivity Scale (EWPS) at baseline and week 8 of a randomized,
placebo-controlled trial of atomoxetine. Clinicians rated symptom severity and improvement (CGI-ADHD-S, CGI-ADHD-I). Responsiveness was examined through
effect sizes and association with change in the measures listed previously (Spearman correlations, GLMs). RESULTS: Analyses included 328 patients
(58.8% male; mean age = 36.9 years). All AAQoL scales reflected significant improvement from baseline to week 8 (P < 0.0001). AAQoL change scores
were significantly correlated with change in the CGI-ADHD-S (r = -0.37 to -0.50), EWPS (r = -0.43 to -0.63), and CAARS (r = -0.35 to -0.62) (all P <
0.001). AAQoL change scores significantly discriminated among patients with various levels of symptom improvement. AAQoL effect sizes (-0.67 to -1.11)
were larger than effect sizes for the SF-36 (0.15 to -0.39). CONCLUSIONS: The AAQoL was responsive to change in symptoms of ADHD, and it appears to be
a useful outcome measure for treatments of ADHD in adults.
Journal: Qual Life Res. 2007 Sep 12
Adapted from PubMed; click here to access full journal article.
Symptom Exaggeration by College Adults in Attention-Deficit Hyperactivity Disorder and Learning Disorder Assessments
Authors: Sullivan BK, May K, Galbally L.
Counseling and Substance Abuse Services, College of Charleston, Charleston, South Carolina, USA.
To test the hypothesis that sub-optimal effort detected by one popular symptom validity measure, the Word Memory Test (WMT), should be interpreted as
symptom exaggeration, the authors examined attention-deficit hyperactivity disorder (ADHD) and learning disorder (LD) assessment data collected from
healthy adult patients over the past four years at one mid-size Southeastern college. They conducted six tests of this hypothesis, drawing upon extant
research. Rates of apparent symptom exaggeration comparable to those found in medicolegal settings (e.g., personal injury cases), particularly in the
context of ADHD evaluations, were found. WMT scores were positively correlated with intellectual and neurocognitive test scores, and negatively correlated
with self-report symptom inventory scores. Measures of negative response bias embedded in one common self-report measure of psychopathology (the
Personality Assessment Inventory) were not correlated with WMT performance. Unattended WMT administrations led to somewhat higher failure rates than
were found when the examiners were present in the room during all phases of the test's administration. In light of considerable secondary gain motives
in this population, the authors conclude that poor effort as evidenced by low WMT scores implies symptom exaggeration and not other factors in these
assessments. The routine inclusion of empirically supported symptom validity measures in these evaluations is recommended, and future research directions
are suggested.
Journal: Appl Neuropsychol. 2007;14(3):189-207.
Adapted from PubMed; click here to access full journal article.
Retrospective Ratings of ADHD Symptoms Made at Young Adulthood by Clinic-Referred Boys with ADHD-Related Problems, Their Brothers
without ADHD, and Control Participants
Authors: Loney J, Ledolter J, Kramer JR, Volpe RJ.
Department of Pediatrics, University of Iowa.
Retrospective childhood attention-deficit/hyperactivity disorder (ADHD) symptoms are required to diagnosis adult ADHD, but the validity of self-rated
symptoms across time is questionable. Here, boys with ADHD-related problems, their brothers without ADHD, and former schoolmates rated themselves
during young adulthood for ages 9, 14, and 19. Brothers rated probands retrospectively at the same ages. The young adults referred as children for
ADHD (a) acknowledged childhood symptoms; (b) described improvement over time; (c) did not differ from brothers or controls on most self-ratings of
young adult symptoms; (d) rated themselves as more symptomatic at age 9, but less symptomatic at age 19, than their brothers rated them; and (e)
agreed only to some degree with brothers' ratings of probands' aggression (median correlation = .22). Probands' ratings showed limited agreement with
judges' symptom ratings (median correlation = .16) and young adult follow-up examiners' ratings (median correlation = .14). These findings are not
accounted for solely by changes in informants, nor by the course of ADHD psychopathology. They suggest some stability but limited internal consistency
and validity for retrospective ADHD ratings by probands and brothers.
Journal: Psychol Assess. 2007 Sep;19(3):269-80.
Adapted from PubMed; click here to access full journal article.
Join Now - Become a free member and get notified about studies in your area when they become available.
Browse Our Current Studies - Look over all of our current studies being conducted throughout the United States.
View Information and Clinical Trials for Other Conditions - Access all of our health-related content.